Moderate

Heart failure with preserved ejection fraction (HFpEF)

Heart failure · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

HF symptoms/signs with LVEF >=50% and objective evidence of raised filling pressures (echo/natriuretic peptides). Typically elderly, hypertensive, obese, diabetic, often with AF. Management targets congestion, comorbidities and now SGLT2i.

Red flags

  • Recurrent flash pulmonary oedema / SCAPE
  • Rapid AF precipitating decompensation
  • Low-flow low-gradient AS masquerading as HFpEF
  • Red-flag features of amyloidosis (bilateral carpal tunnel, low voltage ECG + thick walls)
  • Syncope / conduction disease

Assessment

Differential diagnosis

  • HFrEF / HFmrEF
  • Constrictive pericarditis
  • Cardiac amyloidosis / infiltrative restrictive cardiomyopathy
  • Severe valvular disease (AS, MR)
  • High-output states
  • Non-cardiac dyspnoea (COPD, obesity, deconditioning, PE)

Investigations

  • Echocardiogram — LVEF >=50%, LA enlargement, LV hypertrophy, E/e', diastolic indices
  • NT-proBNP/BNP (may be lower than HFrEF, esp. in obesity — normal does not exclude)
  • ECG (AF, LVH, low voltage/pseudo-infarct suggesting amyloid)
  • U&E, FBC, TFTs, HbA1c, ferritin/TSAT
  • CXR
  • HFA-PEFF or H2FPEF score to support diagnosis; consider exercise/stress echo or invasive haemodynamics if uncertain
  • Screen for cardiac amyloid if red-flags (bone scintigraphy/DPD, serum free light chains)

Management

  • Confirm diagnosis: symptoms + LVEF >=50% + raised filling pressure evidence (echo/NP/invasive)
  • Decongest with loop diuretic titrated to euvolaemia
  • Aggressively treat hypertension to target and manage AF (rate/rhythm, anticoagulate per CHA2DS2-VASc)
  • Start an SGLT2i — now a cornerstone across the EF spectrum
  • Weight loss, exercise rehabilitation, treat sleep apnoea, diabetes, iron deficiency
  • Exclude and specifically treat mimics — especially cardiac amyloidosis (tafamidis) and constriction (pericardiectomy)

Drugs & doses

Dapagliflozin 10 mg PO once daily (SGLT2i — DELIVER) OR Empagliflozin 10 mg PO once daily (EMPEROR-Preserved)
Furosemide 20-40 mg PO once/twice daily titrated to congestion
Spironolactone 25 mg PO once daily (MRA — consider, esp. if LVEF <55-60%; monitor K+)
Finerenone 10-20 mg PO once daily (non-steroidal MRA — FINEARTS-HF benefit in LVEF >=40%) [verify local availability/dose]
Antihypertensives to target BP (ACEi/ARB, CCB, thiazide-like e.g. indapamide 2.5 mg PO once daily)
Rate control for AF: bisoprolol 2.5-5 mg PO once daily or diltiazem (avoid if LVEF borderline) [verify]
Anticoagulation for AF: apixaban 5 mg PO BD (2.5 mg BD if >=2 of age >=80, weight <=60 kg, creatinine >=133)

Disposition

Outpatient optimisation of diuretics, SGLT2i and comorbidities; admit for acute decompensation or arrhythmia. Refer to cardiology/HF clinic, and specifically work up amyloid/constriction where suspected.

Complications & pitfalls

  • Recurrent HF admissions
  • Atrial fibrillation and thromboembolism
  • Pulmonary hypertension and right heart failure
  • Renal dysfunction from over-diuresis
  • Progression if underlying infiltrative disease untreated

Exam pearls

  • SGLT2i are the first class to show consistent benefit in HFpEF (EMPEROR-Preserved, DELIVER) — now guideline-recommended across the EF spectrum.
  • Beta-blockers and RAS blockers have NOT shown clear mortality benefit in true HFpEF — use them to treat comorbidities (HTN, AF, CAD), not the HFpEF itself.
  • Always exclude cardiac amyloidosis — missing it denies a patient disease-modifying tafamidis.
  • Over-diuresis is a common harm — HFpEF patients are preload-dependent and prone to pre-renal AKI and hypotension.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.